IP Group Plc (LON:IPO)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 573.34M +37.0% |
| Revenue (ttm) | 79.80M |
| Net Income | 66.80M |
| EPS | 0.07 |
| Shares Out | 883.43M |
| PE Ratio | 9.14 |
| Forward PE | 11.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,914,041 |
| Open | 63.60 |
| Previous Close | 64.90 |
| Day's Range | 63.30 - 67.10 |
| 52-Week Range | 44.45 - 72.00 |
| Beta | 1.29 |
| Analysts | Strong Buy |
| Price Target | 105.00 (+57.9%) |
| Earnings Date | Jun 17, 2026 |
About IP Group
IP Group Plc is a private equity and venture capital firm specializing in seed/startup, early venture, emerging growth, mature, mid venture, late venture, incubation, mezzanine in growth capital companies. It prefers to invest in energy, materials, healthcare, information technology, communication services, utilities, life sciences, deeptech, cleantech, chemicals, science and innovation companies. The firm prefers to invest in Europe, typically invests in companies based in or willing to relocate to North East England. It firm prefers to invest... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for IPO stock is "Strong Buy." The 12-month stock price target is 105p, which is an increase of 57.90% from the latest price.
News
IP Group price target raised to 110 GBp from 103 GBp at Deutsche Bank
Deutsche Bank raised the firm’s price target on IP Group (IPZYF) to 110 GBp from 103 GBp and keeps a Buy rating on the shares.
IP Group Earnings Call Transcript: H2 2025
NAV per share grew 13% year-over-year, driven by a major royalty interest in Pfizer's obesity drug, strong cash exits, and disciplined buybacks. Portfolio companies raised GBP 900 million in third-party capital, and the group remains focused on deep tech, clean tech, and life sciences.
IP Group Annual report: H2 2025
IP Group has published its H2 2025 annual report on March 17, 2026.
IP Group Slides: H2 2025
IP Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 17, 2026.
IP Group Annual report: H2 2025
IP Group has published its H2 2025 annual report on March 17, 2026.
IP Group price target lowered to 103 GBp from 114 GBp at Deutsche Bank
Deutsche Bank lowered the firm’s price target on IP Group (IPZYF) to 103 GBp from 114 GBp and keeps a Buy rating on the shares.
IP Group Earnings Call Transcript: H1 2025
Strong H1 progress with GBP 30m in exits, robust cash position, and NAV per share rising to GBP 1. Hinge Health IPO and Oxford Nanopore outperformance drove value, while buybacks accelerated. Confident in GBP 250m exit target by 2027 and securing new scale-up mandates.
IP Group Quarterly report: H1 2025
IP Group has published its H1 2025 quarterly earnings report on September 17, 2025.
IP Group Slides: H1 2025
IP Group has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 17, 2025.
IP Group Transcript: CMD 2025
The event outlined a strategy focused on leveraging the U.K.'s scientific strengths to build and scale deep tech businesses, addressing global mega trends in energy, healthcare, and digitalization. With strong government support and a robust investment pipeline, the group is well positioned for growth and value creation.
IP Group initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of IP Group with a Buy rating and 100 GBp price target. The firm does not expect a major improvement in market conditions this year, but…
IP Group price target lowered to 126 GBp from 133 GBp at Berenberg
Berenberg lowered the firm’s price target on IP Group to 126 GBp from 133 GBp and keeps a Buy rating on the shares.